Cybin is a biopharmaceutical company dedicated to developing safe and effective therapeutics using psychedelic and medicinal mushrooms. The company focuses on creating psilocybin-based products in regions where such substances are permitted, while also conducting clinical studies across North America and other areas through collaborations with academic and institutional partners. Cybin's efforts encompass the advancement of psychedelic-based therapies, innovative delivery mechanisms, and the development of novel compounds aimed at addressing a range of mental health issues, including various psychiatric and neurological conditions.
ViewRay, Inc. specializes in the design, manufacture, and marketing of advanced radiation therapy systems, particularly the MRIdian system, which is the first MRI-guided radiation therapy technology that allows simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology with radiation delivery and proprietary software, enabling clinicians to accurately locate, target, and track soft-tissue tumors during treatment. By providing real-time imaging, MRIdian enhances visibility of tumors, thus allowing for precise radiation delivery while minimizing exposure to surrounding healthy tissue. This capability addresses significant limitations of traditional external-beam radiation therapies and expands treatment options for patients who may not have been eligible for radiation therapy previously. ViewRay serves a diverse client base, including university hospitals, community hospitals, and freestanding cancer centers, through a direct sales force and distribution network. The company, founded in 2004 and headquartered in Oakwood, Ohio, has operations in the United States and several European countries.
ViewRay, Inc. specializes in the design, manufacture, and marketing of advanced radiation therapy systems, particularly the MRIdian system, which is the first MRI-guided radiation therapy technology that allows simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology with radiation delivery and proprietary software, enabling clinicians to accurately locate, target, and track soft-tissue tumors during treatment. By providing real-time imaging, MRIdian enhances visibility of tumors, thus allowing for precise radiation delivery while minimizing exposure to surrounding healthy tissue. This capability addresses significant limitations of traditional external-beam radiation therapies and expands treatment options for patients who may not have been eligible for radiation therapy previously. ViewRay serves a diverse client base, including university hospitals, community hospitals, and freestanding cancer centers, through a direct sales force and distribution network. The company, founded in 2004 and headquartered in Oakwood, Ohio, has operations in the United States and several European countries.
ViewRay, Inc. specializes in the design, manufacture, and marketing of advanced radiation therapy systems, particularly the MRIdian system, which is the first MRI-guided radiation therapy technology that allows simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology with radiation delivery and proprietary software, enabling clinicians to accurately locate, target, and track soft-tissue tumors during treatment. By providing real-time imaging, MRIdian enhances visibility of tumors, thus allowing for precise radiation delivery while minimizing exposure to surrounding healthy tissue. This capability addresses significant limitations of traditional external-beam radiation therapies and expands treatment options for patients who may not have been eligible for radiation therapy previously. ViewRay serves a diverse client base, including university hospitals, community hospitals, and freestanding cancer centers, through a direct sales force and distribution network. The company, founded in 2004 and headquartered in Oakwood, Ohio, has operations in the United States and several European countries.
Aerpio Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative treatments for ocular diseases and diabetic complications. Its lead candidate, razuprotafib, is a small molecule that activates the Tie2 pathway and has completed a Phase IIb clinical trial for diabetic retinopathy. The company is also advancing ARP-1536, a humanized monoclonal antibody in preclinical stages for diabetic vascular complications, and GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, currently in a Phase 1b clinical trial for inflammatory bowel disease. Additionally, Aerpio is developing a bispecific antibody for wet age-related macular degeneration and diabetic macular edema. The company collaborates with Quantum Leap Healthcare Collaborative to evaluate razuprotafib for acute respiratory distress syndrome in COVID-19 patients. Founded in 2011 and headquartered in Cincinnati, Ohio, Aerpio emerged from a spin-out from Akebia Therapeutics, leveraging an experienced management team and an outsourced development model.
ViewRay, Inc. specializes in the design, manufacture, and marketing of advanced radiation therapy systems, particularly the MRIdian system, which is the first MRI-guided radiation therapy technology that allows simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology with radiation delivery and proprietary software, enabling clinicians to accurately locate, target, and track soft-tissue tumors during treatment. By providing real-time imaging, MRIdian enhances visibility of tumors, thus allowing for precise radiation delivery while minimizing exposure to surrounding healthy tissue. This capability addresses significant limitations of traditional external-beam radiation therapies and expands treatment options for patients who may not have been eligible for radiation therapy previously. ViewRay serves a diverse client base, including university hospitals, community hospitals, and freestanding cancer centers, through a direct sales force and distribution network. The company, founded in 2004 and headquartered in Oakwood, Ohio, has operations in the United States and several European countries.
TriVascular Technologies, Inc. is a medical device company focused on developing and commercializing technologies for the minimally invasive treatment of abdominal aortic aneurysms (AAA) and thoracic aortic conditions. The company is known for its Ovation System, which includes a stent graft platform designed for endovascular aortic repair. Key components of the Ovation System feature an aortic body, iliac limbs, and polymer fill, which contribute to its effectiveness in treating AAA. TriVascular markets its products through direct sales in the United States and several European countries, as well as via distributors in other regions. Founded in 2007 and headquartered in Santa Rosa, California, TriVascular has been recognized for its innovative approach to addressing unmet clinical needs in aortic disease treatment. The company operates as a subsidiary of Endologix Inc.
Aerpio Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative treatments for ocular diseases and diabetic complications. Its lead candidate, razuprotafib, is a small molecule that activates the Tie2 pathway and has completed a Phase IIb clinical trial for diabetic retinopathy. The company is also advancing ARP-1536, a humanized monoclonal antibody in preclinical stages for diabetic vascular complications, and GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, currently in a Phase 1b clinical trial for inflammatory bowel disease. Additionally, Aerpio is developing a bispecific antibody for wet age-related macular degeneration and diabetic macular edema. The company collaborates with Quantum Leap Healthcare Collaborative to evaluate razuprotafib for acute respiratory distress syndrome in COVID-19 patients. Founded in 2011 and headquartered in Cincinnati, Ohio, Aerpio emerged from a spin-out from Akebia Therapeutics, leveraging an experienced management team and an outsourced development model.
Aerpio Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative treatments for ocular diseases and diabetic complications. Its lead candidate, razuprotafib, is a small molecule that activates the Tie2 pathway and has completed a Phase IIb clinical trial for diabetic retinopathy. The company is also advancing ARP-1536, a humanized monoclonal antibody in preclinical stages for diabetic vascular complications, and GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, currently in a Phase 1b clinical trial for inflammatory bowel disease. Additionally, Aerpio is developing a bispecific antibody for wet age-related macular degeneration and diabetic macular edema. The company collaborates with Quantum Leap Healthcare Collaborative to evaluate razuprotafib for acute respiratory distress syndrome in COVID-19 patients. Founded in 2011 and headquartered in Cincinnati, Ohio, Aerpio emerged from a spin-out from Akebia Therapeutics, leveraging an experienced management team and an outsourced development model.
Boreal Genomics Inc. is a biotechnology company that focuses on the development and commercialization of technologies for blood-based detection and monitoring of circulating tumor DNA. Founded in 2007 and headquartered in Los Altos, California, with an additional office in Vancouver, Canada, the company offers products like OnTarget, which allows for the sensitive detection and quantification of tumor mutations in plasma or tissue. Boreal's platform is designed to enable healthcare professionals to perform accurate genomic profiling and monitor tumor evolution from cell-free DNA in plasma, thereby improving cancer patient care. The OnTarget assay, available as a research-use service, reveals tumor mutations that may be undetectable by other methods, assisting in therapy selection, enhancing clinical trial efficiency, and expediting drug development. Additionally, Boreal provides DNA enrichment and library construction solutions tailored for high accuracy sequencing in liquid biopsy applications.
Akebia Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing treatments for kidney diseases. Its lead product, Auryxia, is a ferric citrate formulation used to manage serum phosphorus levels in adults with chronic kidney disease, particularly those on dialysis. The company is also advancing vadadustat, an oral therapy in Phase III development aimed at treating anemia in patients with chronic kidney disease, both on dialysis and non-dialysis. Akebia has formed collaboration agreements with Otsuka Pharmaceutical for the development of vadadustat in various global markets and with Mitsubishi Tanabe Pharma for its development in Japan and other Asian regions. Additionally, the company has a research and licensing agreement with Janssen Pharmaceutica for compounds targeting hypoxia-inducible factors. Founded in 2007, Akebia Therapeutics is headquartered in Cambridge, Massachusetts.
ViewRay, Inc. specializes in the design, manufacture, and marketing of advanced radiation therapy systems, particularly the MRIdian system, which is the first MRI-guided radiation therapy technology that allows simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology with radiation delivery and proprietary software, enabling clinicians to accurately locate, target, and track soft-tissue tumors during treatment. By providing real-time imaging, MRIdian enhances visibility of tumors, thus allowing for precise radiation delivery while minimizing exposure to surrounding healthy tissue. This capability addresses significant limitations of traditional external-beam radiation therapies and expands treatment options for patients who may not have been eligible for radiation therapy previously. ViewRay serves a diverse client base, including university hospitals, community hospitals, and freestanding cancer centers, through a direct sales force and distribution network. The company, founded in 2004 and headquartered in Oakwood, Ohio, has operations in the United States and several European countries.
Aerpio Pharmaceuticals is a biopharmaceutical company dedicated to developing innovative treatments for ocular diseases and diabetic complications. Its lead candidate, razuprotafib, is a small molecule that activates the Tie2 pathway and has completed a Phase IIb clinical trial for diabetic retinopathy. The company is also advancing ARP-1536, a humanized monoclonal antibody in preclinical stages for diabetic vascular complications, and GB004, a selective stabilizer of hypoxia-inducible factor-1 alpha, currently in a Phase 1b clinical trial for inflammatory bowel disease. Additionally, Aerpio is developing a bispecific antibody for wet age-related macular degeneration and diabetic macular edema. The company collaborates with Quantum Leap Healthcare Collaborative to evaluate razuprotafib for acute respiratory distress syndrome in COVID-19 patients. Founded in 2011 and headquartered in Cincinnati, Ohio, Aerpio emerged from a spin-out from Akebia Therapeutics, leveraging an experienced management team and an outsourced development model.
TriVascular Technologies, Inc. is a medical device company focused on developing and commercializing technologies for the minimally invasive treatment of abdominal aortic aneurysms (AAA) and thoracic aortic conditions. The company is known for its Ovation System, which includes a stent graft platform designed for endovascular aortic repair. Key components of the Ovation System feature an aortic body, iliac limbs, and polymer fill, which contribute to its effectiveness in treating AAA. TriVascular markets its products through direct sales in the United States and several European countries, as well as via distributors in other regions. Founded in 2007 and headquartered in Santa Rosa, California, TriVascular has been recognized for its innovative approach to addressing unmet clinical needs in aortic disease treatment. The company operates as a subsidiary of Endologix Inc.
ViewRay, Inc. specializes in the design, manufacture, and marketing of advanced radiation therapy systems, particularly the MRIdian system, which is the first MRI-guided radiation therapy technology that allows simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology with radiation delivery and proprietary software, enabling clinicians to accurately locate, target, and track soft-tissue tumors during treatment. By providing real-time imaging, MRIdian enhances visibility of tumors, thus allowing for precise radiation delivery while minimizing exposure to surrounding healthy tissue. This capability addresses significant limitations of traditional external-beam radiation therapies and expands treatment options for patients who may not have been eligible for radiation therapy previously. ViewRay serves a diverse client base, including university hospitals, community hospitals, and freestanding cancer centers, through a direct sales force and distribution network. The company, founded in 2004 and headquartered in Oakwood, Ohio, has operations in the United States and several European countries.
ViewRay, Inc. specializes in the design, manufacture, and marketing of advanced radiation therapy systems, particularly the MRIdian system, which is the first MRI-guided radiation therapy technology that allows simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology with radiation delivery and proprietary software, enabling clinicians to accurately locate, target, and track soft-tissue tumors during treatment. By providing real-time imaging, MRIdian enhances visibility of tumors, thus allowing for precise radiation delivery while minimizing exposure to surrounding healthy tissue. This capability addresses significant limitations of traditional external-beam radiation therapies and expands treatment options for patients who may not have been eligible for radiation therapy previously. ViewRay serves a diverse client base, including university hospitals, community hospitals, and freestanding cancer centers, through a direct sales force and distribution network. The company, founded in 2004 and headquartered in Oakwood, Ohio, has operations in the United States and several European countries.
Akebia Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing treatments for kidney diseases. Its lead product, Auryxia, is a ferric citrate formulation used to manage serum phosphorus levels in adults with chronic kidney disease, particularly those on dialysis. The company is also advancing vadadustat, an oral therapy in Phase III development aimed at treating anemia in patients with chronic kidney disease, both on dialysis and non-dialysis. Akebia has formed collaboration agreements with Otsuka Pharmaceutical for the development of vadadustat in various global markets and with Mitsubishi Tanabe Pharma for its development in Japan and other Asian regions. Additionally, the company has a research and licensing agreement with Janssen Pharmaceutica for compounds targeting hypoxia-inducible factors. Founded in 2007, Akebia Therapeutics is headquartered in Cambridge, Massachusetts.
NextWave Pharmaceuticals is a Cupertino, California-based pharmaceutical company that specializes in the development and commercialization of innovative drug delivery technologies. The company primarily focuses on creating once-daily liquid medications for the treatment of attention deficit/hyperactivity disorder (ADHD). By leveraging its proprietary technology, NextWave aims to provide effective treatment options that enhance patient compliance and address disorders related to the central nervous system.
ViewRay, Inc. specializes in the design, manufacture, and marketing of advanced radiation therapy systems, particularly the MRIdian system, which is the first MRI-guided radiation therapy technology that allows simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology with radiation delivery and proprietary software, enabling clinicians to accurately locate, target, and track soft-tissue tumors during treatment. By providing real-time imaging, MRIdian enhances visibility of tumors, thus allowing for precise radiation delivery while minimizing exposure to surrounding healthy tissue. This capability addresses significant limitations of traditional external-beam radiation therapies and expands treatment options for patients who may not have been eligible for radiation therapy previously. ViewRay serves a diverse client base, including university hospitals, community hospitals, and freestanding cancer centers, through a direct sales force and distribution network. The company, founded in 2004 and headquartered in Oakwood, Ohio, has operations in the United States and several European countries.
TriVascular Technologies, Inc. is a medical device company focused on developing and commercializing technologies for the minimally invasive treatment of abdominal aortic aneurysms (AAA) and thoracic aortic conditions. The company is known for its Ovation System, which includes a stent graft platform designed for endovascular aortic repair. Key components of the Ovation System feature an aortic body, iliac limbs, and polymer fill, which contribute to its effectiveness in treating AAA. TriVascular markets its products through direct sales in the United States and several European countries, as well as via distributors in other regions. Founded in 2007 and headquartered in Santa Rosa, California, TriVascular has been recognized for its innovative approach to addressing unmet clinical needs in aortic disease treatment. The company operates as a subsidiary of Endologix Inc.
Baxano, Inc. specializes in the development of minimally invasive tools aimed at restoring spine function while preserving healthy tissue. Based in San Jose, California, the company offers the iO-Flex System, designed to target and decompress bone and soft tissue in areas such as the foramen, lateral recess, and central canal, catering to patients with varying degrees of stenosis. Its product line includes the Neuro Check device, which enables surgeons to verify that the device is positioned against the bone with the nerve safely out of the way. Additionally, Baxano provides the MicroBlade Shaver instrument for the removal of impinging bone and ligament, along with essential tools like guidewires, probes, and distal handles. Founded in 2005, Baxano continues to innovate in the field of spinal health.
TriVascular Technologies, Inc. is a medical device company focused on developing and commercializing technologies for the minimally invasive treatment of abdominal aortic aneurysms (AAA) and thoracic aortic conditions. The company is known for its Ovation System, which includes a stent graft platform designed for endovascular aortic repair. Key components of the Ovation System feature an aortic body, iliac limbs, and polymer fill, which contribute to its effectiveness in treating AAA. TriVascular markets its products through direct sales in the United States and several European countries, as well as via distributors in other regions. Founded in 2007 and headquartered in Santa Rosa, California, TriVascular has been recognized for its innovative approach to addressing unmet clinical needs in aortic disease treatment. The company operates as a subsidiary of Endologix Inc.
Akebia Therapeutics, Inc. is a biopharmaceutical company dedicated to developing and commercializing treatments for kidney diseases. Its lead product, Auryxia, is a ferric citrate formulation used to manage serum phosphorus levels in adults with chronic kidney disease, particularly those on dialysis. The company is also advancing vadadustat, an oral therapy in Phase III development aimed at treating anemia in patients with chronic kidney disease, both on dialysis and non-dialysis. Akebia has formed collaboration agreements with Otsuka Pharmaceutical for the development of vadadustat in various global markets and with Mitsubishi Tanabe Pharma for its development in Japan and other Asian regions. Additionally, the company has a research and licensing agreement with Janssen Pharmaceutica for compounds targeting hypoxia-inducible factors. Founded in 2007, Akebia Therapeutics is headquartered in Cambridge, Massachusetts.
Baxano, Inc. specializes in the development of minimally invasive tools aimed at restoring spine function while preserving healthy tissue. Based in San Jose, California, the company offers the iO-Flex System, designed to target and decompress bone and soft tissue in areas such as the foramen, lateral recess, and central canal, catering to patients with varying degrees of stenosis. Its product line includes the Neuro Check device, which enables surgeons to verify that the device is positioned against the bone with the nerve safely out of the way. Additionally, Baxano provides the MicroBlade Shaver instrument for the removal of impinging bone and ligament, along with essential tools like guidewires, probes, and distal handles. Founded in 2005, Baxano continues to innovate in the field of spinal health.
TriVascular Technologies, Inc. is a medical device company focused on developing and commercializing technologies for the minimally invasive treatment of abdominal aortic aneurysms (AAA) and thoracic aortic conditions. The company is known for its Ovation System, which includes a stent graft platform designed for endovascular aortic repair. Key components of the Ovation System feature an aortic body, iliac limbs, and polymer fill, which contribute to its effectiveness in treating AAA. TriVascular markets its products through direct sales in the United States and several European countries, as well as via distributors in other regions. Founded in 2007 and headquartered in Santa Rosa, California, TriVascular has been recognized for its innovative approach to addressing unmet clinical needs in aortic disease treatment. The company operates as a subsidiary of Endologix Inc.
ViewRay, Inc. specializes in the design, manufacture, and marketing of advanced radiation therapy systems, particularly the MRIdian system, which is the first MRI-guided radiation therapy technology that allows simultaneous imaging and treatment of cancer patients. This innovative system integrates MRI technology with radiation delivery and proprietary software, enabling clinicians to accurately locate, target, and track soft-tissue tumors during treatment. By providing real-time imaging, MRIdian enhances visibility of tumors, thus allowing for precise radiation delivery while minimizing exposure to surrounding healthy tissue. This capability addresses significant limitations of traditional external-beam radiation therapies and expands treatment options for patients who may not have been eligible for radiation therapy previously. ViewRay serves a diverse client base, including university hospitals, community hospitals, and freestanding cancer centers, through a direct sales force and distribution network. The company, founded in 2004 and headquartered in Oakwood, Ohio, has operations in the United States and several European countries.
CVRx, Inc. is a medical device company based in Minneapolis, Minnesota, that specializes in implantable technology for treating high blood pressure and heart failure. The company develops Barostim, a proprietary neuromodulation therapy that activates the body's natural reflexes to regulate blood pressure and address the progression of heart failure. This therapy is delivered through a long-lasting implant system that is tailored to meet individual patient needs. CVRx also manufactures the Rheos implantable pulse generator and associated components, which facilitate the delivery of activation energy to the carotid arteries. Founded in 2000, CVRx primarily serves patients and healthcare professionals in the United States and several European countries, focusing on minimally invasive solutions for cardiovascular diseases.